GlobeNewsWire·3 days ago
Halper Sadeh LLC is Investigating Whether BOLD and NDRA are Obtaining Fair Deals for their ShareholdersInsiders may stand to receive substantial financial benefits not available to ordinary shareholders.
Boundless Bio, Inc.(BOLD)Earnings, Financials & Key Ratios
BOLD•NASDAQ
$2.48
Price updated Jul 2, 2026
AboutBoundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.Show more
- Revenue$0
- EBITDA-$62M+13.7%
- Net Income-$58M+11.0%
- EPS (Diluted)-2.60+32.5%
- ROE-46.69%+91.6%
BOLD Price & Volume
Boundless Bio, Inc. (BOLD) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Threaten Liquidity Runway Sustainability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Critical Clinical Funding Gap
Key Thesis Takeaways
- Boundless Bio remains a high-risk, pre-revenue biotechnology firm heavily reliant on the successful advancement of its ecDNA-targeted oncology pipeline.
- While the company continues to invest in its proprietary Spyglass platform, the persistent quarterly net losses, which reached $13.6 million in 2026Q1, necessitate urgent capital raises to avoid further liquidity erosion.
- Investors should monitor the company's ability to secure non-dilutive funding or strategic partnerships, as the current cash position of $17.5 million provides a limited buffer against ongoing R&D expenditures.
Verdict Logic
the company's cash position has dwindled to $17.5 million as of 2026Q1, creating a critical funding gap that threatens the continuity of its clinical trials.
BOLD Growth Metrics
Boundless Bio, Inc. (BOLD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM14.76%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM18.3%
Return on Capital
10 Years-44.55%
5 Years-40.37%
3 Years-46.94%
Last Year-37.08%
BOLD Recent Earnings
Boundless Bio, Inc. (BOLD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (33%)
Q2 2026Latest
May 8, 2026Metric
Actual
Est
EPS
$0.60-4.0%
$0.58
Rev
—
—
Q2 2026
Mar 9, 2026Metric
Actual
Est
EPS
$0.58-31.8%
$0.44
Rev
—
—
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.62-17.0%
$0.53
Rev
—
—
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.70+6.7%
$0.75
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 8, 2026 | $0.60vs $0.58-4.0% | — |
| Q2 2026 | Mar 9, 2026 | $0.58vs $0.44-31.8% | — |
| Q4 2025 | Nov 5, 2025 | $0.62vs $0.53-17.0% | — |
| Q3 2025 | Aug 5, 2025 | $0.70vs $0.75+6.7% | — |
Based on last 12 quarters of dataView full earnings history →
Latest BOLD News
Recent stock market news and headlines for Boundless Bio, Inc. (BOLD)
GuruFocus·Jun 25, 2026
Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders?Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 25, 2026
Business Wire·Jun 23, 2026
BOLD Stock Alert: Halper Sadeh LLC is Investigating Whether Boundless Bio, Inc. is Obtaining a Fair Price for its ShareholdersNEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Boundless Bio, Inc. (NASDAQ: BOLD) and Serapha Bio, Inc. Upon closing of the proposed transaction, Boundless Bio shareholders are expected to own approximately 3.7% of the combined company.Halper Sadeh encourages Boundless Bio shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.
GlobeNewsWire·Jun 23, 2026
Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private PlacementCombined company to operate as Serapha Bio and to advance Serapha's potential best-in-class in vivo base editing program for Alpha-1 Antitrypsin Deficiency
Peers Comparison
Key metrics vs top competitors for Boundless Bio, Inc. (BOLD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.48 | $55.71M | -0.95 | — | — | -46.69% | — | |
| $4.62 | $293.66M | -3.92 | 0.78% | -44.79% | -147.8% | — | |
| $5.07 | $205.84M | 4.16 | 36.55% | -19.55% | -3.39% | — | |
| $38.14 | $7.83B | -13.77 | — | — | -68.16% | — | |
| $114.20 | $9.32B | -30.95 | -16.72% | -612.17% | -25.02% | — | |
| $3.41 | $142M | -1002.94 | 10.37% | 52.16% | — | — |
Compare BOLD vs Peers
Boundless Bio, Inc. (BOLD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BOLD SEC Filings & Documents
Boundless Bio, Inc. (BOLD) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 8, 2026·SEC
Material company update
Apr 13, 2026·SEC
Material company update
Mar 9, 2026·SEC
10-K Annual Reports
210-Q Quarterly Reports
6Get notified when BOLD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BOLD Frequently Asked Questions
Boundless Bio, Inc. (BOLD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is BOLD profitable?
Boundless Bio, Inc. (BOLD) reported a net loss of $56.0M for fiscal year 2025.
Dividend & Returns
What is BOLD's return on equity?
Boundless Bio, Inc. (BOLD) has a return on equity (ROE) of -46.7%. Negative ROE indicates the company is unprofitable.
What is Boundless Bio, Inc.'s free cash flow?
Boundless Bio, Inc. (BOLD) had negative free cash flow of $47.6M in fiscal year 2025, likely due to heavy capital investments.